Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (EU5) – 2020
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by branded targeted therapies. In the EGFR-positive setting, Tarceva (Roche) and Giotrif (Boehringer Ingelheim) are facing increasing competition from Tagrisso (AstraZeneca) and Vizimpro (Pfizer). In other key populations, the PD-1 inhibitor Keytruda (Merck & Co.) continues to dominate due to its demonstrated survival benefit. However, novel immune checkpoint inhibitor combinations incorporating Tecentriq (Roche) with Avastin (Roche) and/or chemotherapy will compete and provide alternative treatment options. Our primary research provides insight into the current use of approved therapies for NSCLC in the EU5 and uncovers key factors that influence medical oncologists’ prescribing decisions.
QUESTIONS ANSWERED
- What are the treatment rates in the various lines of therapy for metastatic NSCLC?
- How are newly approved agents for EGFR-positive (Tagrisso, Vizimpro) and ALK-translocation-positive (Alunbrig, Lorviqua) NSCLC changing the treatment landscape for specific patients?
- How are Keytruda- and Tecentriq-based chemotherapy regimens performing in the first-line metastatic NSCLC setting? Which regimen do the EU5 physicians favor? Does it change according to geography?
- What are the main obstacles in prescribing immune checkpoint inhibitors (as monotherapies or combination approaches) forNSCLC?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: France, Germany, Italy, Spain, and the United Kingdom
Primary research: Survey of 50 medical oncologists in each EU5 country.
Key drugs covered: Keytruda, Opdivo, Tecentriq, Imfinzi, Avastin, Tarceva, Iressa, Giotrif, Tagrisso, Vizimpro, Xalkori, Zykadia, Alecensa, Alunbrig, Lorviqua, Tafinlar, Mekinist
Vandana Singh, M.Pharm., is an associate analyst on the Oncology team at Clarivate. Previously, she was a business analyst in digital marketing at Iquanti in Bangalore. She also conducted competitive intelligence, forecasting, and pipeline analysis at WNS in Noida. She obtained her master’s degree in pharmacology from the University of Delhi.